Lakefront Biotherapeutics (LKFT) Raw Materials (2021 - 2025)
Lakefront Biotherapeutics (LKFT) posted quarterly Raw Materials of $26.2 million for Q4 2025, down 52.14% year-over-year from $54.7 million in Q4 2024, and down 52.14% quarter-over-quarter from $54.7 million in Q4 2024.
Lakefront Biotherapeutics (LKFT) Raw Materials (2021 - 2025) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Raw Materials for 5 consecutive years, with $26.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Raw Materials fell 52.14% year-over-year to $26.2 million; the TTM figure through Dec 2025 stood at $26.2 million (down 52.14% YoY), while the FY2025 annual figure was $26.2 million, down 52.14% from the prior year.
- Raw Materials retreated to $26.2 million in Q4 2025 per LKFT's latest filing, from $54.7 million in the prior quarter.
- Across five years, Raw Materials topped out at $59.5 million in Q4 2023 and bottomed at $16.4 million in Q4 2021.
- Historically, Raw Materials has averaged $39.3 million across 5 years, with a median of $39.9 million in 2022.
- Annual changes were most pronounced in 2022 — Raw Materials soared 142.81% — and 2025, when it sank 52.14%.
- Lakefront Biotherapeutics' Raw Materials stood at $16.4 million in 2021, then jumped by 142.81% to $39.9 million in 2022, then soared by 49.16% to $59.5 million in 2023, then decreased by 8.0% to $54.7 million in 2024, then tumbled by 52.14% to $26.2 million in 2025.
- Business Quant data shows LKFT's Raw Materials at $26.2 million in Q4 2025, $54.7 million in Q4 2024, and $59.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.18 Mn |
| Dec 31, 2024 | 54.70 Mn |
| Dec 31, 2023 | 59.46 Mn |
| Dec 31, 2022 | 39.86 Mn |
| Dec 31, 2021 | 16.42 Mn |